Answers are grounded in this paper and cite their sources.
Longitudinal increase of plasma pTau181 and glial fibrillary acidic protein (GFAP) can be measured in the preclinical phase of AD. Apolipoprotein E ε4 carriers experience faster increase in plasma pTau181 over time than non-carriers. Female sex showed accelerated increase in plasma GFAP over time compared to males. Aβ42/40 and pTau231 values are already abnormal at baseline in individuals with both amyloid and tau PET burden.
No takes yet. Share an insight, caveat, or question.
Yakoub et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: